RealFeedApp David Liu will return to ESGCT in 2019
Nobel laureate David Liu stated that the synergy between scientific approaches and regulatory advances allows expanding genome editing applications beyond rare genetic diseases.
- Field
- gene therapy
- What they did
- David Liu emphasizes that scientific methods in gene therapy must work together with regulatory and manufacturing advances to treat not only rare diseases but also over 8,000 known genetic disorders.
- Why it matters
- This is necessary to overcome the current limitation where gene editing is effective for only a very small fraction of patients with genetic disorders.
#gene editing#crispr#clinical trial#david liu#esgct
